Aytu BioScience

121 articles with Aytu BioScience

• Aytu BioPharma to Present at Upcoming June Investor Conferences

  5/25/2021

  Aytu BioPharma, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced that Josh Disbrow, Chairman and Chief Executive Officer, will present at two upcoming investor conferences in June:

• Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021

  5/10/2021

  Aytu BioPharma, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced that it will host a conference call and live webcast on Monday, May 17, 2021, at 4:30 p.m. ET to report its financial results for the fiscal third quarter ended March 31, 2021 and review recent accomplishments.

• Aytu BioScience Announces Close of Merger with Neos Therapeutics

  3/22/2021

  Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced the closing of its merger with Neos Therapeutics.

• Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

  3/10/2021

  The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time

• Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients

  3/8/2021

  Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from a first in-human, open label, clinical trial in SARS-CoV-2 patients has been released.

• Aytu BioScience to Present at Upcoming March Investor Conferences

  2/24/2021

  Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at three upcoming investor conferences in March: Cowen 41 st Annual Healthcare Conference :

• Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year

  2/11/2021

  Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty pharmaceutical company Q2 Consumer Health division revenue reaches an all-time high of $7.9 million Q2 Rx division revenue up 24% sequentially

• Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021

  2/10/2021

  Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc.

• Aytu BioScience to Report Second Fiscal 2021 Results and Provide Business Update on Thursday, February 11, 2021

  2/4/2021

  Aytu BioScience, Inc. (NASDAQ:AYTU) , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal second quarter ended December 31, 2020 on February 11, 2021, at 4:30 p.m. ET.

• Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients

  12/28/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the Healight; ultraviolet A light catheter technology.

• Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

  12/15/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU), , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underwritten public offering of 4,791,667 shares of common stock of the Company, which includes the full exercise of the underwriters option to purchase an additional 625,000 shares

• Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET

  12/14/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU) , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that management will present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET.

• Aytu BioScience Announces $10.0 Million Bought Deal Offering

  12/10/2020

  Aytu BioScience, Inc. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions.

• Aytu BioScience Increases Previously Announced Bought Deal Offering to $25.0 Million

  12/10/2020

  Aytu BioScience, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4,166,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions.

• Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company

  12/10/2020

  Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company

• Aytu BioScience Announces Fiscal Q1 2021 Net Revenue of $13.5 Million, an Increase of 839% Year-Over-Year

  11/12/2020

  Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs reported financial results for its fiscal first quarter 2021, for the three month period ending September 30, 2020.

• Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET

  11/11/2020

  Aytu BioScience, Inc. announced today that management will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference on Wednesday, November 18 at 1:45pm ET / 6:45pm GMT.

• Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020

  11/5/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU) a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal first quarter ended September 30, 2020 on November 12, 2020, at 4:30 p.m. ET.

• Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020

  10/5/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU) announced today that the Company will present its operational results for the fiscal fourth quarter and year ended June 30, 2020 on October 6, 2020, at 4:30 p.m. ET.

• Aytu BioScience to Reschedule Fourth Quarter and FY 2020 Conference Call

  9/23/2020

  Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it will reschedule its fourth quarter and FY 2020 conference call, previously scheduled for Thursday, September 24 at 4:30pm ET.